BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23239149)

  • 1. Vimentin DNA methylation predicts survival in breast cancer.
    Ulirsch J; Fan C; Knafl G; Wu MJ; Coleman B; Perou CM; Swift-Scanlan T
    Breast Cancer Res Treat; 2013 Jan; 137(2):383-96. PubMed ID: 23239149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women.
    Izadi P; Mehrdad N; Foruzandeh F; Reza NM
    Asian Pac J Cancer Prev; 2012; 13(8):4113-7. PubMed ID: 23098526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vimentin as a poor prognostic factor for triple-negative breast cancer.
    Yamashita N; Tokunaga E; Kitao H; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Aishima S; Morita M; Maehara Y
    J Cancer Res Clin Oncol; 2013 May; 139(5):739-46. PubMed ID: 23354842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival.
    Conway K; Edmiston SN; May R; Kuan PF; Chu H; Bryant C; Tse CK; Swift-Scanlan T; Geradts J; Troester MA; Millikan RC
    Breast Cancer Res; 2014 Oct; 16(5):450. PubMed ID: 25287138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy.
    Huang YT; Li FF; Ke C; Li Z; Li ZT; Zou XF; Zheng XX; Chen YP; Zhang H
    J Transl Med; 2013 Oct; 11():245. PubMed ID: 24090193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOXD13 methylation status is a prognostic indicator in breast cancer.
    Zhong Z; Shan M; Wang J; Liu T; Xia B; Niu M; Ren Y; Pang D
    Int J Clin Exp Pathol; 2015; 8(9):10716-24. PubMed ID: 26617782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.
    Lo PK; Lee JS; Liang X; Sukumar S
    Cell Signal; 2016 Oct; 28(10):1502-19. PubMed ID: 27377963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
    Holm K; Staaf J; Lauss M; Aine M; Lindgren D; Bendahl PO; Vallon-Christersson J; Barkardottir RB; Höglund M; Borg Å; Jönsson G; Ringnér M
    Breast Cancer Res; 2016 Feb; 18(1):27. PubMed ID: 26923702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
    Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
    Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer.
    Cheng CW; Wang HW; Chang CW; Chu HW; Chen CY; Yu JC; Chao JI; Liu HF; Ding SL; Shen CY
    Breast Cancer Res Treat; 2012 Aug; 134(3):1081-93. PubMed ID: 22476851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter.
    Poli E; Zhang J; Nwachukwu C; Zheng Y; Adedokun B; Olopade OI; Han YJ
    PLoS One; 2015; 10(11):e0142224. PubMed ID: 26539832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG island shore methylation regulates caveolin-1 expression in breast cancer.
    Rao X; Evans J; Chae H; Pilrose J; Kim S; Yan P; Huang RL; Lai HC; Lin H; Liu Y; Miller D; Rhee JK; Huang YW; Gu F; Gray JW; Huang TM; Nephew KP
    Oncogene; 2013 Sep; 32(38):4519-28. PubMed ID: 23128390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal-like breast cancer displays distinct patterns of promoter methylation.
    Lee JS; Fackler MJ; Lee JH; Choi C; Park MH; Yoon JH; Zhang Z; Sukumar S
    Cancer Biol Ther; 2010 Jun; 9(12):1017-24. PubMed ID: 20505321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns.
    Holm K; Hegardt C; Staaf J; Vallon-Christersson J; Jönsson G; Olsson H; Borg A; Ringnér M
    Breast Cancer Res; 2010; 12(3):R36. PubMed ID: 20565864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of DNAJC10 (ERDJ5) is associated with poor survival in breast cancer.
    Acun T; Senses KM
    Breast Cancer; 2020 May; 27(3):483-489. PubMed ID: 31902119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of methylation sites and signature genes with prognostic value for luminal breast cancer.
    Xiao B; Chen L; Ke Y; Hang J; Cao L; Zhang R; Zhang W; Liao Y; Gao Y; Chen J; Li L; Hao W; Sun Z; Li L
    BMC Cancer; 2018 Apr; 18(1):405. PubMed ID: 29642861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients.
    Li SY; Li R; Chen YL; Xiong LK; Wang HL; Rong L; Luo RC
    BMC Genet; 2014 Jun; 15():67. PubMed ID: 24919593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis.
    Perez-Janices N; Blanco-Luquin I; Torrea N; Liechtenstein T; Escors D; Cordoba A; Vicente-Garcia F; Jauregui I; De La Cruz S; Illarramendi JJ; Coca V; Berdasco M; Kochan G; Ibañez B; Lera JM; Guerrero-Setas D
    Oncotarget; 2015 Sep; 6(27):23944-58. PubMed ID: 26284587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.